Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study-Reference-Cited by-同舟云学术

Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study

Published:2015-05 Issue:5 Volume:16 Page:541-549
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Roschewski Mark,Dunleavy Kieron,Pittaluga Stefania,Moorhead Martin,Pepin Francois,Kong Katherine,Shovlin Margaret,Jaffe Elaine S,Staudt Louis M,Lai Catherine,Steinberg Seth M,Chen Clara C,Zheng Jianbiao,Willis Thomas D,Faham Malek,Wilson Wyndham H

Publisher

Elsevier BV

Subject

Oncology

Reference31 articles.

1. The histological and biological spectrum of diffuse large B-cell lymphoma in the World Health Organization classification;Menon;Cancer J,2012

2. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era;Gisselbrecht;J Clin Oncol,2010

3. Surveillance imaging during remission identifies a group of patients with more favorable aggressive NHL at time of relapse: a retrospective analysis of a uniformly-treated patient population;Liedtke;Ann Oncol,2006

4. Who benefits from surveillance imaging?;Armitage;J Clin Oncol,2012

5. Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in advanced-stage diffuse large B-cell lymphoma;Moskowitz;J Clin Oncol,2010

Cited by 358 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Next Questions in Aggressive B-cell Lymphomas;Clinical Lymphoma Myeloma and Leukemia;2024-09

2. Minimal Residual Disease Testing for Classical Hodgkin Lymphoma: A Comprehensive Review;Critical Reviews in Oncology/Hematology;2024-09

3. Clinical applications of circulating tumor DNA in hematological malignancies: From past to the future;Blood Reviews;2024-09

4. Minimal residual disease detection in lymphoma: methods, procedures and clinical significance;Frontiers in Immunology;2024-08-12

5. New and developing first line pharmacotherapies for treating non-Hodgkin lymphoma;Expert Opinion on Pharmacotherapy;2024-08-12